Discovers, develops, and commercializes therapeutic compounds. Focuses on inhibiting the complement system to treat autoimmune and inflammatory diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 97% a year over the last 4 years. Red columns mark years that ended in a loss.
The two sides balance each other out — the picture is neither a safety net nor an alarm.
The market pays 234.6× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 51% above today's price.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 97% a year on average.
The company’s market value is 235 times its annual profit. Even a small disappointment could hit the price hard.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.